This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

EYLEA® (aflibercept) 8 mg real-world evidence

Real-world outcomes in treatment-naïve and previously treated patients with nAMD

The Royal Wolverhampton NHS Trust

These data are from real patients. Individual results may vary.

Study design:

Retrospective study evaluated visual acuity and central retinal thickness in 62 treatment-naïve eyes and 24 previously treated eyes with nAMD. **The mean follow-up was 8.2 months and 9.9 months for treatment-naïve and previously treated patients, respectively.**

All patients received three initial monthly doses of EYLEA 8 mg followed by a T&E protocol. **Safety parameters were not assessed in this study.**

Patient demographics in treatment-naïve patients

Eyes, N	62
Age range, years	63–98
Female, %	54.8

Treatment-naïve patients

Fast and sustained drying with EYLEA 8 mg

Mean change in CRT over time



−108 µm

Mean change in CRT from baseline through a mean follow up duration of 8.2 months (N=62)

Fluid-free status

82.3%
of patients achieved **fluid-free status** after **three loading doses**

2.2 injections
on average were required for patients to **reach fluid-free status**

Vision gains with EYLEA 8 mg

Mean change in VA over time



+3.9
ETDRS letters

Mean change in VA from baseline through a mean follow up duration of 8.2 months (N=62)

Treatment intervals with EYLEA 8 mg

10.4 weeks
Mean final planned interval

11.2 weeks
Mean interval after the loading phase

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.

Abbreviations:
CRT, central retinal thickness; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **nAMD**, neovascular age-related macular degeneration; **T&E**, treat-and-extend; **VA**, visual acuity.

Reference:
Bayer UK Data on File_PP-EYL-GB-3075_December 2025.

May 2026 | PP-EYL_8mg-GB-1038

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

Previously treated patients

Patient demographics in previously treated patients	
Eyes, N	24
Age range, years	67–92
Female, %	58.3

Proportion of patients receiving anti-VEGF medication prior to switch

38.5
mean injections with other anti-VEGF agents were given prior to switch



- Proportion of patients that have not been switched before*
- Proportion of patients that have switched treatment once†
- Proportion of patients that have switched treatment twice‡

Longer treatment intervals were observed with EYLEA 8 mg vs previous anti-VEGFs

Mean treatment intervals prior to switch to EYLEA 8 mg



Mean treatment intervals after switch to EYLEA 8 mg



Mean change in interval of +2.6 weeks from baseline through 9.9 months (N=24)

Maintained fluid control with EYLEA 8 mg

Mean change in CRT over time



+11.6 µm

Mean change in CRT in previously treated patients from baseline through 9.9 months (N=24)

Fluid-free status

62.5%
of patients achieved **fluid-free status** after **three loading doses**

2.5 injections
on average were required for patients to **reach fluid-free status**

Maintained vision with EYLEA 8 mg

Mean change in VA over time



–1.7 ETDRS letters

Mean change in VA in previously treated patients from baseline through 9.9 months (N=24)

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.

*Received monotherapy with EYLEA 2 mg, faricimab or ranibizumab. †Received treatment with two anti-VEGFs (EYLEA 2 mg / faricimab / ranibizumab). ‡Received treatment with EYLEA 2 mg, faricimab and ranibizumab. §One patient was defined as inactive as chronic fluid did not worsen following observation; therefore, the decision was made to withhold treatment and the patient remained stable.

Abbreviations:
CRT, central retinal thickness; **ETDRS,** Early Treatment Diabetic Retinopathy Study; **qX**, every X weeks; **VA**, visual acuity; **VEGF**, vascular endothelial growth factor.

Reference:
Bayer UK Data on File_PP-EYL-GB-3075_December 2025.

May 2026 | PP-EYL_8mg-GB-1038

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.